Apellis Pharmaceuticals (APLS) Earnings Announcement Scheduled

Apellis Pharmaceuticals (NASDAQ:APLS) is set to announce its earnings before the market opens on Tuesday, February 25th. Analysts anticipate that the company will report a loss of ($0.37) per share, with revenues expected to reach approximately $197.92 million for the quarter. Interested individuals can register for the company's earnings conference call using the provided link.

Current Trading Status

As of Tuesday, APLS opened at $27.40. The company's market capitalization stands at $3.41 billion, with a price-to-earnings ratio of -13.50 and a beta of 0.96. It has a 50-day moving average of $31.05 and a 200-day moving average of $32.03. Over the past year, Apellis Pharmaceuticals has seen a low of $24.34 and a high of $71.90. The company also shows a quick ratio of 3.73 and a current ratio of 4.36, with a debt-to-equity ratio of 1.91.

Analyst Opinions

Apellis Pharmaceuticals has received attention from several analysts. Morgan Stanley initiated coverage on the stock and gave it an 'equal weight' rating along with a price target of $31.00. Robert W. Baird decreased their target price from $92.00 to $55.00 while maintaining an 'outperform' rating. Mizuho revised their price target down from $39.00 to $38.00, issuing a 'neutral' rating. Wells Fargo & Company also reduced their price target from $43.00 to $30.00, keeping an 'equal weight' rating. Additionally, Royal Bank of Canada reaffirmed a 'sector perform' rating with a target price of $26.00. Overall, eight analysts have a hold rating on the stock, ten have given it a buy rating, and one has rated it as a strong buy. Based on MarketBeat data, Apellis Pharmaceuticals has a consensus rating of 'Moderate Buy' with an average target price of $46.71.

Recent Insider Trading

In related news, CAO James George Chopas sold 1,096 shares of Apellis stock on January 22nd at an average price of $30.43, totaling $33,351.28. After the sale, he owns 48,138 shares valued at approximately $1.46 million, reflecting a 2.23% decrease in his stake. Additionally, CFO Timothy Eugene Sullivan sold 1,730 shares on January 17th for $51,830.80 at an average price of $29.96. Post-sale, he holds 86,370 shares worth about $2.59 million, marking a 1.96% decrease. Over the last three months, insiders have sold 60,365 shares worth $1.81 million, with insiders holding 6.80% of the stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies that inhibit the complement system to treat autoimmune and inflammatory diseases. The company markets EMPAVELI, a treatment for conditions such as paroxysmal nocturnal hemoglobinuria, and SYFOVRE, used for geographic atrophy due to age-related macular degeneration.

Earnings, Stocks, Company